Name of the Procedure:

Injection of sacituzumab govitecan-hziy, 2.5 mg (HCPCS Code: C9066)

Summary

This procedure involves the injection of sacituzumab govitecan-hziy, a medication used in cancer treatment. It is designed to deliver targeted therapy for specific types of advanced cancers.

Purpose

Sacituzumab govitecan-hziy targets and kills cancer cells. The procedure aims to reduce tumor size, slow down the progression of the disease, and improve survival and quality of life for patients with certain types of advanced cancers, such as metastatic triple-negative breast cancer.

Indications

• Metastatic triple-negative breast cancer (mTNBC)
• Patients who have previously undergone at least two lines of therapy for metastatic disease
• Symptoms such as rapid tumor progression or lack of response to other treatments

Preparation

• No specific fasting required, but patients should follow any personalized instructions from their healthcare provider.
• Blood tests or imaging studies may be performed to assess the current status of the disease and overall health.
• Inform the healthcare provider of any medications, allergies, or underlying health conditions.

Procedure Description

1. Consultation: A discussion with the oncologist to review the treatment plan.
2. Pre-Injection: Vital signs are checked, and an IV line is inserted if needed.
3. Injection: The sacituzumab govitecan-hziy is administered as an intravenous injection.
4. Monitoring: The patient is observed for any immediate side effects following the injection.

Tools/Equipment:

• IV line and sterile needles
• Sacituzumab govitecan-hziy medication

Anesthesia/Sedation Details:

• Typically, no anesthesia is needed as it is an IV injection.

Duration

The injection process usually takes about 30 to 60 minutes, including setup and post-injection monitoring.

Setting

Performed in a hospital's oncology department, outpatient clinic, or a specialized infusion center.

Personnel

• Oncologist
• Oncology nurse
• Medical assistants

Risks and Complications

• Common Risks: Nausea, fatigue, diarrhea, neutropenia (low white blood cell count)
• Rare Risks: Severe infusion reactions, anaphylaxis, severe neutropenia or infections
• Management: Monitoring by healthcare providers, appropriate medications, and supportive care.

Benefits

• Reduction in tumor size
• Slowing the progression of cancer
• Improvement in survival rates and quality of life
• Benefits may be noticed within weeks to months of starting treatment

Recovery

• Regular follow-up appointments to monitor response and manage side effects
• Blood tests to check for side effects such as low blood cell counts
• Patients can usually resume normal activities shortly after the injection, but fatigue may be experienced.

Alternatives

• Other chemotherapy regimens
• Targeted therapy with different agents
• Radiation therapy
• Clinical trials with experimental treatments

Pros/Cons of Alternatives:

• Chemotherapy: Broadly effective but with higher side-effect profiles.
• Different Targeted Therapy: May be less effective if not specific to the patient's cancer type.
• Radiation Therapy: Localized to specific areas, may not affect distant metastases.
• Clinical Trials: Access to new treatments but with unknown effectiveness and safety profiles.

Patient Experience

• Patients might feel a slight pinch or discomfort at the injection site.
• Possible side effects such as nausea or fatigue post-injection.
• Pain management and supportive care will be provided as needed.
• Most patients can expect manageable discomfort and gradual improvement in their condition.